Skip to main content

Worldwide Molecular Diagnostics Industry To 2031 - Rise Of Next-Generation Ultrasensitive Molecular Diagnostics Presents Opportunities

DUBLIN, Dec. 2, 2021 /PRNewswire/ -- The "Molecular Diagnostics Market - A Global and Regional Analysis: Focus on Product, Testing Location, Application, Technology, and End User - Analysis and Forecast, 2021-2031" report has been added to...

DUBLIN, Dec. 2, 2021 /PRNewswire/ -- The "Molecular Diagnostics Market - A Global and Regional Analysis: Focus on Product, Testing Location, Application, Technology, and End User - Analysis and Forecast, 2021-2031" report has been added to ResearchAndMarkets.com's offering.

The global molecular diagnostics market is projected to reach $24,228.0 million by 2031 from $10,914.6 million in 2020, at a CAGR of 7.38% during the forecast period 2021-2031.

Market Report Coverage - Molecular Diagnostics Market Segmentation

  • Products (Kits and Consumables, Systems, Software and Other Products)
  • Testing Location (Laboratory Testing and Point-of-Care (POC) Testing)
  • Application (Core Molecular Diagnostics, Reproductive Genetics, Companion Diagnostics (CDx), Liquid Biopsy, and Others)
  • Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing, Isothermal Nucleic Acid Amplification Technology (INAAT), Microarray, In-situ Hybridization (ISH), Immunohistochemistry (IHC) and Other Technologies)
  • End User (Hospitals, Diagnostics Centers, Out-Patient Clinics/General Practitioners, Research Laboratories, and Other End Users)

Key Companies Profiled

Abbott, Agilent Technologies, Inc., Becton, Dickinson and Company (BD), bioMerieux SA, Bio-Rad Laboratories, Inc., Danaher, F. Hoffmann-La Roche Ltd, Guardant Health, HTG Molecular Diagnostics, Inc., Illumina, Inc., Invivoscribe, Inc., ICON plc, LungLife AI, Inc., QIAGEN, QuantuMDx Group Ltd., Siemens Healthcare GmbH, Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:

  • How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment?
  • What are the major market drivers, challenges, and opportunities in the global molecular diagnostics market?
  • What are the underlying structures resulting in the emerging trends within the global molecular diagnostics market?
  • How is each segment of the global molecular diagnostics market expected to grow during the forecast period, and what will be the expected revenue generated by each of the segments by the end of 2031?
  • What are the key developmental strategies implemented by the major players to sustain in the competitive market?
  • What are the key regulatory implications in developed and developing regions for molecular diagnostics?
  • Who are the leading players with significant offerings to the global molecular diagnostics market? What is the current market dominance for each of these leading players?
  • What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2021-2031? Which molecular diagnostic product type has the most promising growth?
  • What are the key applications in the global molecular diagnostics market? What are the major segments of these applications? What technologies are dominating these application segments?
  • What are the major technologies that are employed in the global molecular diagnostics market? Which is the dominating technology?
  • Who are the primary end-users of the global molecular diagnostics market? Which is the fastest-growing end-user segment in the global molecular diagnostics market?
  • Who are the key manufacturers in the global molecular diagnostics market, and what are their contributions? Also, what is the growth potential of each major molecular diagnostics manufacturer?
  • What is the scope of the global molecular diagnostics market in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World? Which molecular diagnostics application and end user dominate these regions?
  • What are the emerging trends in the global molecular diagnostics market? How are these trends revolutionizing the diagnostic procedure?
  • Which technologies are anticipated to break through the current molecular diagnostic regime?
  • Which companies are anticipated to be highly disruptive in the future and why?
  • What are the regulatory procedures that are required to unify the approval process for emerging molecular diagnostics? How will these enhance the reimbursement scenario?
  • What are the gaps in regularizing optimum molecular diagnostic adoption in regular healthcare routines? How are these gaps being tackled?

Key Topics Covered:

1 Markets1.1 Product Definition1.1.1 Definitions1.1.2 Inclusion and Exclusion1.2 Market Overview1.3 Historical Perspective1.4 Significant Technologies1.5 Classification of Molecular Diagnostics1.6 Global Footprint1.7 Global Molecular Diagnostics Market Size and Forecast - Realistic, Optimistic, and Conservative Growth Scenario1.7.1 Realistic Growth Scenario1.7.2 Conservative Growth Scenario1.8 Future Potential1.8.1 Optimistic Growth Scenario1.9 Market Dynamics1.9.1 Impact Analysis1.9.2 Market Drivers1.9.2.1 A Highly Increasing Prevalence of Infectious Diseases and Various Types of Cancer, Globally1.9.2.2 Growth in the Biomarker Identification Market and Advancements in Molecular Techniques1.9.2.3 Increase in Awareness and Acceptance of Personalized Medicines on a Global Level1.9.2.4 Significant External Funding for Executing Research and Development Exercises1.9.3 Market Restraints1.9.3.1 Uncertain Reimbursement Scenario1.9.3.2 Lack of High-Complexity Testing Centers1.9.3.3 Complex Regulatory Frameworks Delaying the Approval of New Molecular Diagnostic Tests1.9.4 Market Opportunities1.9.4.1 Massive Scope for Adoption of Molecular Diagnostics in Emerging Nations1.9.4.2 Rise of Next-Generation Ultrasensitive Molecular Diagnostics1.9.4.3 Novel Revenue Streams1.1 COVID-19 Impact on Global Molecular Diagnostics Market1.10.1 Impact on Market Size1.10.2 Impact on Molecular Diagnostic Practices1.11 Competitive Landscape1.11.1 Acquisitions1.11.2 Synergistic Activities1.11.3 Product Launches and Upgradations1.11.4 Business Expansion1.11.5 Market Share Analysis, by Company1.11.6 Growth Share Analysis, by Technology1.12 Industry Insights1.12.1 Legal Requirements and Framework in the U.S.1.12.2 FDA Regulations1.12.3 Legal Requirements and Framework in Europe1.12.3.1 U.K.1.12.3.2 Germany1.12.4 Legal Requirements and Framework in Asia-Pacific1.12.4.1 China1.12.4.2 Japan1.12.4.2.1 Pharmaceuticals and Medical Devices Agency (PMDA)1.12.4.2.2 Ministry of Health, Labour, and Welfare (MHLW)1.12.4.3 India1.13 Patent Analysis1.13.1 Patent Filing Trend

2 Products2.1 Overview2.1.1 Systems2.1.2 Kits and Consumables2.1.3 Software and Other Products

3 Testing Location3.1 Overview3.1.1 Laboratory Testing3.1.2 Point-of-Care Testing

4 Technology4.1 Overview4.1.1 Polymerase Chain Reaction (PCR)4.1.2 Next-Generation Sequencing4.1.3 Isothermal Nucleic Acid Amplification Technology (INAAT)4.1.4 Microarray4.1.5 In-Situ Hybridization (ISH)4.1.6 Immunohistochemistry (IHC)4.1.7 Other Technologies

5 Application5.1 Overview5.1.1 Core Molecular Diagnostics5.1.1.1 Infectious Disease5.1.1.1.1 Respiratory Infections5.1.1.1.1.1 Influenza A and B5.1.1.1.1.2 COVID-19 Infections5.1.1.1.1.3 Respiratory Syncytial Virus5.1.1.1.1.4 Mycoplasma Infections5.1.1.1.1.5 Pertussis5.1.1.1.1.6 Other Respiratory Infections5.1.1.1.2 Sexual Transmitted Infections(STI)5.1.1.1.2.1 Common Pathogens Associated with Sexually Transmitted Infection5.1.1.1.2.2 Hepatitis B5.1.1.1.2.3 HIV-AIDS5.1.1.1.2.4 HPV5.1.1.1.2.5 Herpes Simplex Virus5.1.1.1.2.6 Neisseria Gonorrhoeae5.1.1.1.2.7 Other STIs5.1.1.2 Hereditary Genetic Testing5.1.1.3 Blood Donor Screening5.1.1.4 Oncology5.1.1.5 Human Leukocyte Antigen (HLA) Testing5.1.1.6 Other Molecular Diagnostics Applications5.1.2 Reproductive Genetics5.1.2.1 Carrier Screening5.1.2.2 Non-Invasive Pre-Natal Testing (NIPT)5.1.2.3 Pre-Implantation Genetic Testing5.1.2.4 Infertility Genetic Testing5.1.3 Companion Diagnostics (CDx)5.1.4 Liquid Biopsy5.1.5 Other Applications

6 End-User6.1 Overview6.1.1 Hospitals6.1.1.1 Hospitals, by Respiratory Infections Molecular Diagnostics Market6.1.1.1.1 Hospitals, by Influenza A and B6.1.1.1.2 Hospitals, by COVID-19 Infections6.1.1.1.3 Hospitals, by Respiratory Syncytial Virus6.1.1.1.4 Hospitals, by Mycoplasma Infection6.1.1.1.5 Hospitals, by Pertussis6.1.1.1.6 Hospitals, by Other Respiratory Infections6.1.1.2 Hospitals Sexually Transmitted Infections (STIs) Market6.1.1.2.1 Hospitals, by Hepatitis B6.1.1.2.2 Hospitals, by HIV AIDS6.1.1.2.3 Hospitals, by HPV6.1.1.2.4 Hospitals, by Herpes Simplex Virus(HSV)6.1.1.2.5 Hospitals, by Neisseria gonorrhoeae6.1.1.2.6 Hospitals, by Other STIs6.1.2 Diagnostic Centers6.1.2.1 Diagnostic Centers, by Respiratory Infections Molecular Diagnostics Market6.1.2.1.1 Diagnostic Centers, by Influenza A and B6.1.2.1.2 Diagnostic Centers, by COVID-19 Infections6.1.2.1.3 Diagnostic Centers, by Respiratory Syncytial Virus6.1.2.1.4 Diagnostic Centers, by Mycoplasma Infection6.1.2.1.5 Diagnostic Centers, by Pertussis6.1.2.1.6 Diagnostic Centers, by Other Respiratory Infections6.1.2.2 Diagnostic Centers Sexually Transmitted Infections (STIs) Market6.1.2.2.1 Diagnostic Centers, by Hepatitis B6.1.2.2.2 Diagnostic Centers, by HIV AIDS6.1.2.2.3 Diagnostic Centers, by HPV6.1.2.2.4 Diagnostic Centers, by Herpes Simplex Virus(HSV)6.1.2.2.5 Diagnostic Centers, by Neisseria gonorrhoeae6.1.2.2.6 Diagnostic Centers, by Other STIs6.1.3 Out-Patient Clinics/General Practitioners6.1.3.1 Out-Patient Clinics/General Practitioners, by Respiratory Infections Molecular Diagnostics Market6.1.3.1.1 Out-Patient Clinics/General Practitioners, by Influenza A and B6.1.3.1.2 Out-Patient Clinics/General Practitioners, by COVID-19 Infections6.1.3.1.3 Out-Patient Clinics/General Practitioners, by Respiratory Syncytial Virus6.1.3.1.4 Out-Patient Clinics/General Practitioners, by Mycoplasma Infection6.1.3.1.5 Out-Patient Clinics/General Practitioners, by Pertussis6.1.3.1.6 Out-Patient Clinics/General Practitioners, by Other Respiratory Infections6.1.3.2 Out-Patient Clinics/General Practitioners Sexually Transmitted Infections (STIs) Market6.1.3.2.1 Out-Patient Clinics/General Practitioners, by Hepatitis B6.1.3.2.2 Out-Patient Clinics/General Practitioners, by HIV AIDS6.1.3.2.3 Out-Patient Clinics/General Practitioners, by HPV6.1.3.2.4 Out-Patient Clinics/General Practitioners, by Herpes Simplex Virus(HSV)6.1.3.2.5 Out-Patient Clinics/General Practitioners, by Neisseria gonorrhoeae6.1.3.2.6 Out-Patient Clinics/General Practitioners, by Other STIs6.1.4 Research Laboratories6.1.4.1 Research Laboratories, by Respiratory Infections Molecular Diagnostics Market6.1.4.1.1 Research Laboratories, by Influenza A and B6.1.4.1.2 Research Laboratories, by COVID-19 Infections6.1.4.1.3 Research Laboratories, by Respiratory Syncytial Virus6.1.4.1.4 Research Laboratories, by Mycoplasma Infection6.1.4.1.5 Research Laboratories, by Pertussis6.1.4.1.6 Research Laboratories, by Other Respiratory Infections6.1.4.2 Research Laboratories Sexually Transmitted Infections (STIs) Market6.1.4.2.1 Research Laboratories, by Hepatitis B6.1.4.2.2 Research Laboratories, by HIV AIDS6.1.4.2.3 Research Laboratories, by HPV6.1.4.2.4 Research Laboratories, by Herpes Simplex Virus(HSV)6.1.4.2.5 Research Laboratories, by Neisseria gonorrhoeae6.1.4.2.6 Research Laboratories, by Other STIs6.1.5 Other End Users

7 Regions

8 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/30fqxq

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com    For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

View original content: https://www.prnewswire.com/news-releases/worldwide-molecular-diagnostics-industry-to-2031---rise-of-next-generation-ultrasensitive-molecular-diagnostics-presents-opportunities-301436053.html

SOURCE Research and Markets